Free provider profile
RENA FERGUSON, MD
NPI 1013082452
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2026-02-09.
251 E OAKLAND AVE STE 2A, PORT JEFFERSON, NY, 11777
631-760-1830
Single practice location
Enumerated 2006-11-21
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 1 payer identifiers on file — enrolled with payers.
- — Record updated within the last year.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
1,604
Medicare patients
181
Part D drug cost
$534,871
Brand-name share
14.3%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Austedo Xr (Deutetrabenazine) | 13 | $117,087 |
| Rexulti (Brexpiprazole) | 26 | $86,686 |
| Austedo (Deutetrabenazine) | 16 | $49,687 |
| Caplyta (Lumateperone Tosylate) | 20 | $40,668 |
| Auvelity (Dextromethorphan Hbr/Bupropion) | 18 | $36,605 |
| Spravato (Esketamine Hcl) | 18 | $23,696 |
| Belsomra (Suvorexant) | 24 | $9,032 |
| Fetzima (Levomilnacipran Hcl) | 17 | $8,693 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024214 sessions · 15 patients · $216,930
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.